Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus FERNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus FERNISONE.
CORTENEMA vs FERNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
FERNISONE is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
40 mg orally once daily
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life: 18-24 hours in healthy adults. In elderly (age >65), half-life increases to 30-36 hours due to reduced renal function. In moderate renal impairment (CrCl 30-60 mL/min), half-life extends to 40-48 hours. Clinical context: requires dose adjustment in renal impairment; steady-state reached in 3-5 days.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal excretion of unchanged drug and metabolites: ~60% (30% unchanged, 30% metabolites). Biliary/fecal elimination: ~35% (primarily as metabolites). Minor metabolic clearance via CYP3A4. About 5% eliminated in sweat and saliva.
Category C
Category C
Corticosteroid
Corticosteroid